Department of Pathology, Massachusetts General Hospital, Boston, USA.
Harvard Medical School, Boston, USA.
Histopathology. 2024 Aug;85(2):263-274. doi: 10.1111/his.15198. Epub 2024 Apr 25.
Small invasive carcinomas arising in intraductal papillary mucinous neoplasms (IPMNs) of the pancreas can present as multiple, small foci. In such cases, there is no clear optimal measurement method for determining the invasive size for tumour staging and prognostication.
In all, 117 small invasive IPMNs (size of largest invasive component ≤2 cm) from seven institutions (2000-2016) were reviewed, and all individual foci of invasive carcinoma were measured. T stages (AJCC 8th edition) based on the largest single focus size (LS), average size of all foci (AS), and total sum of all foci (TS) were examined in association with clinicopathologic parameters and patient outcomes.
The cohort comprised IPMNs with invasive tubular-type (n = 82, 70%) and colloid-type (n = 35, 30%) carcinomas. The mean LS, AS, and TS were 0.86, 0.71, and 1.32 cm, respectively. Based on the LS, AS, and TS, respectively, 48, 65, and 39 cases were classified as pT1a; 22, 18, and 11 cases as pT1b; and 47, 34, and 50 cases as pT1c. Higher pT stages based on all measurements were significantly associated with small vessel, large vessel, and perineural invasion (P < 0.05). LS-, AS-, and TS-based pT stages were not significantly associated with recurrence-free survival (RFS) or overall survival (OS) by univariate or multivariate analyses. However, among tubular-type carcinomas, higher LS-, AS-, and TS-based pT stages trended with lower RFS (based on 1-, 3-, and 5-year survival rates). All microscopic measurement methods were most predictive of RFS and OS using a 1.5-cm cutoff, with LS significantly associated with both RFS and OS by univariate and multivariate analysis.
For invasive tubular-type carcinomas arising in IPMN, microscopic size-based AJCC pT stages were not significant predictors of patient outcomes. However, for LS, a size threshold of 1.5 cm was optimal for stratifying both RFS and OS. The AJCC 8th ed. may not be applicable for stratifying small invasive IPMNs with colloid-type histology that generally portend a more favourable prognosis.
胰腺内导管乳头状黏液性肿瘤(IPMN)中发生的小浸润性癌可表现为多个小病灶。在这种情况下,尚无明确的最佳测量方法来确定肿瘤分期和预后的浸润大小。
回顾了来自 7 家机构(2000-2016 年)的 117 例小侵袭性 IPMN(最大侵袭性成分大小≤2cm),并测量了所有侵袭性癌的单个病灶。根据最大单个病灶大小(LS)、所有病灶的平均大小(AS)和所有病灶的总和(TS),检查了基于第 8 版 AJCC 的 T 分期与临床病理参数和患者预后的关系。
该队列包括浸润性管状型(n=82,70%)和胶样型(n=35,30%)癌的 IPMN。LS、AS 和 TS 的平均值分别为 0.86cm、0.71cm 和 1.32cm。根据 LS、AS 和 TS,分别有 48、65 和 39 例病例被归类为 pT1a;22、18 和 11 例为 pT1b;47、34 和 50 例为 pT1c。基于所有测量值的更高 pT 分期与小血管、大血管和神经周围侵犯显著相关(P<0.05)。LS、AS 和 TS 基于的 pT 分期与无复发生存率(RFS)或总生存率(OS)均无显著相关性,无论是单因素分析还是多因素分析。然而,在管状型癌中,更高的 LS、AS 和 TS 基于的 pT 分期与较低的 RFS 趋势相关(基于 1、3 和 5 年生存率)。所有显微镜测量方法在使用 1.5cm 截止值时对 RFS 和 OS 的预测最为准确,LS 经单因素和多因素分析均与 RFS 和 OS 显著相关。
对于起源于 IPMN 的浸润性管状型癌,基于显微镜大小的 AJCC pT 分期不是患者预后的显著预测因素。然而,对于 LS,1.5cm 的大小阈值是分层 RFS 和 OS 的最佳选择。对于第 8 版 AJCC 可能不适用于预测具有胶样组织学的小浸润性 IPMN,后者通常预示着预后更好。